This live virtual meeting brought together expert clinicians to discuss BRUKINSA, a next-generation BTK inhibitor, as a treatment option for patients with CLL.  

Topics included clinical evidence supporting the use of BRUKINSA, patient case studies, the use of BRUKINSA in the NHS, and concluded with a panel-led Q&A session. 

On-demand video content from this meeting will be available soon.  

Agenda